{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:23:03Z","timestamp":1794082983703,"version":"4.8.0"},"reference-count":69,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2022,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of viscosupplementation for pain and function in patients with knee osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of randomised trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Searches were conducted of Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to 11 September 2021. Unpublished trials were identified from the grey literature and trial registries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for study selection<\/jats:title>\n                    <jats:p>Randomised trials comparing viscosupplementation with placebo or no intervention for knee osteoarthritis treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The prespecified primary outcome was pain intensity. Secondary outcomes were function and serious adverse events. Pain and function were analysed as standardised mean differences (SMDs). The prespecified minimal clinically important between group difference was \u22120.37 SMD. Serious adverse events were analysed as relative risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two reviewers independently extracted relevant data and assessed the risk of bias of trials using the Cochrane risk of bias tool. The predefined main analysis was based only on large, placebo controlled trials with \u2265100 participants per group. Summary results were obtained through a random effects meta-analysis model. Cumulative meta-analysis and trial sequential analysis under a random effects model were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>169 trials provided data on 21\u2009163 randomised participants. Evidence of small study effects and publication biases was observed for pain and function (Egger\u2019s tests with P&lt;0.001 and asymmetric funnel plots). Twenty four large, placebo controlled trials (8997 randomised participants) included in the main analysis of pain indicated that viscosupplementation was associated with a small reduction in pain intensity compared with placebo (SMD \u22120.08, 95% confidence interval \u22120.15 to \u22120.02), with the lower bound of the 95% confidence interval excluding the minimal clinically important between group difference. This effect corresponds to a difference in pain scores of \u22122.0 mm (95% confidence interval \u22123.8 to \u22120.5 mm) on a 100 mm visual analogue scale. Trial sequential analysis for pain indicated that since 2009 there has been conclusive evidence of clinical equivalence between viscosupplementation and placebo. Similar conclusions were obtained for function. Based on 15 large, placebo controlled trials on 6462 randomised participants, viscosupplementation was associated with a statistically significant higher risk of serious adverse events than placebo (relative risk 1.49, 95% confidence interval 1.12 to 1.98).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Strong conclusive evidence indicates that viscosupplementation leads to a small reduction in knee osteoarthritis pain compared with placebo, but the difference is less than the minimal clinically important between group difference. Strong conclusive evidence indicates that viscosupplementation is also associated with an increased risk of serious adverse events compared with placebo. The findings do not support broad use of viscosupplementation for the treatment of knee osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42021236894.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2022-069722","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T20:02:26Z","timestamp":1657137746000},"page":"e069722","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":154,"title":["Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis"],"prefix":"10.1136","volume":"378","clinical-trial-number":[{"clinical-trial-number":"nct02495857","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02495857","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01934218","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01372475","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00988091","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01934218","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01934218","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tiago V","family":"Pereira","sequence":"first","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, Toronto, ON, Canada"},{"name":"Department of Health Sciences, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, Toronto, ON, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakeezah","family":"Saadat","sequence":"additional","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, Toronto, ON, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xing","sequence":"additional","affiliation":[{"name":"Arthritis Clinic & Research Centre, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Bobos","sequence":"additional","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, Toronto, ON, Canada"},{"name":"Department of Health and Rehabilitation Sciences, School of Physical Therapy, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A","family":"Hincapi\u00e9","sequence":"additional","affiliation":[{"name":"Department of Chiropractic Medicine, Faculty of Medicine, Balgrist University Hospital and University of Zurich, Zurich, Switzerland"},{"name":"Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-6332","authenticated-orcid":false,"given":"Bruno R","family":"da Costa","sequence":"additional","affiliation":[{"name":"Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, Toronto, ON, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada"},{"name":"Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2025110101540835000_378.jul06_19.e069722.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30417-9"},{"key":"2025110101540835000_378.jul06_19.e069722.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1903768"},{"key":"2025110101540835000_378.jul06_19.e069722.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100587"},{"key":"2025110101540835000_378.jul06_19.e069722.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0123-4"},{"key":"2025110101540835000_378.jul06_19.e069722.5","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-197110000-00006"},{"key":"2025110101540835000_378.jul06_19.e069722.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.152"},{"key":"2025110101540835000_378.jul06_19.e069722.7","first-page":"278","article-title":"Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results","volume":"12","author":"Balazs","year":"2004","journal-title":"Surg Technol Int"},{"key":"2025110101540835000_378.jul06_19.e069722.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22171"},{"key":"2025110101540835000_378.jul06_19.e069722.9","unstructured":"NICE. Osteoarthritis: care and management. Clinical guideline [CG177].https:\/\/www.nice.org.uk\/guidance\/cg177\/chapter\/Recommendations#pharmacological-management%202014 (accessed May 8, 2022)"},{"key":"2025110101540835000_378.jul06_19.e069722.10","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S194669"},{"key":"2025110101540835000_378.jul06_19.e069722.11","doi-asserted-by":"publisher","DOI":"10.1177\/11795441211047284"},{"key":"2025110101540835000_378.jul06_19.e069722.12","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.21.00832"},{"key":"2025110101540835000_378.jul06_19.e069722.13","first-page":"56","article-title":"Insights from real-world analysis of treatment patterns in patients with newly diagnosed knee osteoarthritis","volume":"14","author":"Dysart","year":"2021","journal-title":"Am Health Drug Benefits"},{"key":"2025110101540835000_378.jul06_19.e069722.14","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.3926"},{"key":"2025110101540835000_378.jul06_19.e069722.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"2025110101540835000_378.jul06_19.e069722.16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005321.pub2"},{"key":"2025110101540835000_378.jul06_19.e069722.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1215534"},{"key":"2025110101540835000_378.jul06_19.e069722.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.05.002"},{"key":"2025110101540835000_378.jul06_19.e069722.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-8-200704170-00009"},{"key":"2025110101540835000_378.jul06_19.e069722.20","unstructured":"European Comission. Clinical investigations. Serious adverse event reporting under directives 90\/385\/EEC and 93\/42\/EEC. Brussels, Belgium: European Commission; 2015. https:\/\/ec.europa.eu\/docsroom\/documents\/16477\/attachments\/1\/translations\/en\/renditions\/pdf (accessed Sep 1, 2021)."},{"key":"2025110101540835000_378.jul06_19.e069722.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"2025110101540835000_378.jul06_19.e069722.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025110101540835000_378.jul06_19.e069722.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2321"},{"issue":"10","key":"2025110101540835000_378.jul06_19.e069722.24","article-title":"Intra-articular corticosteroid for knee osteoarthritis","author":"J\u00fcni","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025110101540835000_378.jul06_19.e069722.25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-3-201208070-00473"},{"key":"2025110101540835000_378.jul06_19.e069722.26","doi-asserted-by":"crossref","unstructured":"Wandel S, J\u00fcni P, Tendal B, N\u00fcesch E, Villiger PM, Welton NJ et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341:c4675:c4675.","DOI":"10.1136\/bmj.c4675"},{"key":"2025110101540835000_378.jul06_19.e069722.27","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025110101540835000_378.jul06_19.e069722.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3515"},{"key":"2025110101540835000_378.jul06_19.e069722.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu424"},{"key":"2025110101540835000_378.jul06_19.e069722.30","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"2025110101540835000_378.jul06_19.e069722.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.1536"},{"key":"2025110101540835000_378.jul06_19.e069722.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7280.226"},{"key":"2025110101540835000_378.jul06_19.e069722.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025110101540835000_378.jul06_19.e069722.34","first-page":"280","article-title":"[Clinical evaluation of sodium hyaluronate in the treatment of osteoarthritis of the knee]","volume":"23","author":"Shichikawa","year":"1983","journal-title":"Ryumachi"},{"key":"2025110101540835000_378.jul06_19.e069722.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(05)80329-2"},{"key":"2025110101540835000_378.jul06_19.e069722.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.7.424"},{"key":"2025110101540835000_378.jul06_19.e069722.37","first-page":"2203","article-title":"Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial","volume":"25","author":"Altman","year":"1998","journal-title":"J Rheumatol"},{"key":"2025110101540835000_378.jul06_19.e069722.38","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200104000-00021"},{"key":"2025110101540835000_378.jul06_19.e069722.39","unstructured":"Seikagaku Corporation. Summary of safety and effectiveness data: Sodiumhyaluronate. Bethesda, MD. U.S. Food and Drug Administration; 2001. [UK]. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170016B.pdf (accessed Oct 21, 2021)."},{"key":"2025110101540835000_378.jul06_19.e069722.40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1742-1241.2003.tb10535.x","article-title":"A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee","volume":"57","author":"Jubb","year":"2003","journal-title":"Int J Clin Pract"},{"key":"2025110101540835000_378.jul06_19.e069722.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2004.04.010"},{"key":"2025110101540835000_378.jul06_19.e069722.42","first-page":"775","article-title":"A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee","volume":"31","author":"Day","year":"2004","journal-title":"J Rheumatol"},{"key":"2025110101540835000_378.jul06_19.e069722.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019703"},{"key":"2025110101540835000_378.jul06_19.e069722.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.04.001"},{"key":"2025110101540835000_378.jul06_19.e069722.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2008.06.014"},{"key":"2025110101540835000_378.jul06_19.e069722.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094623"},{"key":"2025110101540835000_378.jul06_19.e069722.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118042"},{"key":"2025110101540835000_378.jul06_19.e069722.48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-221"},{"key":"2025110101540835000_378.jul06_19.e069722.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2012.01.013"},{"key":"2025110101540835000_378.jul06_19.e069722.50","unstructured":"Ferring Pharmaceuticals. A 26 week, double-blind, randomized, placebo-controlled study of the efficacy and safety of single intra-articular injection 1.2% sodium hyaluronate for treatment of painful osteoarthritis of the knee, with optional 26-week open-label safety extension). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00988091 (accessed 1 Sep 2021)."},{"key":"2025110101540835000_378.jul06_19.e069722.51","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.855631"},{"key":"2025110101540835000_378.jul06_19.e069722.52","unstructured":"Fidia Farmaceutici A. Multi-centre, double-blind, randomized, placebo controlled study to evaluate the safety and effectiveness of a new viscoelastic hydrogel (Hymovis) in the treatment of knee oa with an open-label extension. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01372475; https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150010b.pdf (accessed 21 Oct 2021)."},{"key":"2025110101540835000_378.jul06_19.e069722.53","unstructured":"Seikagaku Corporation. A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular Injection of Gel-One? for the Treatment of Osteoarthritis of the Knee With Open-Label Safety Extension. https:\/\/clinicaltrials gov\/ct2\/show\/NCT01934218 and https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf8\/P080020S020B.pdf (accessed Oct 21, 2021)."},{"key":"2025110101540835000_378.jul06_19.e069722.54","doi-asserted-by":"publisher","DOI":"10.1177\/1947603517703732"},{"key":"2025110101540835000_378.jul06_19.e069722.55","doi-asserted-by":"publisher","DOI":"10.1007\/s00167-018-5114-0"},{"key":"2025110101540835000_378.jul06_19.e069722.56","unstructured":"Teva Pharmaceuticals. A double-blind, randomized, study of the effectiveness and safety of hyaluronate injectable viscosupplement for treatment of osteoarthritis of the knee. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02495857 and https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170016B.pdf (accessed 21 Oct 2021)."},{"key":"2025110101540835000_378.jul06_19.e069722.57","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04252-2"},{"key":"2025110101540835000_378.jul06_19.e069722.58","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00363-3"},{"key":"2025110101540835000_378.jul06_19.e069722.59","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13192"},{"key":"2025110101540835000_378.jul06_19.e069722.60","doi-asserted-by":"publisher","DOI":"10.1177\/1947603518768015"},{"key":"2025110101540835000_378.jul06_19.e069722.61","doi-asserted-by":"publisher","DOI":"10.1038\/srep32790"},{"key":"2025110101540835000_378.jul06_19.e069722.62","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"J Rheumatol"},{"key":"2025110101540835000_378.jul06_19.e069722.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2003.09.004"},{"key":"2025110101540835000_378.jul06_19.e069722.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2005.06.012"},{"key":"2025110101540835000_378.jul06_19.e069722.65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4732"},{"key":"2025110101540835000_378.jul06_19.e069722.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2019.06.011"},{"key":"2025110101540835000_378.jul06_19.e069722.67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7523"},{"key":"2025110101540835000_378.jul06_19.e069722.68","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7048.36"},{"key":"2025110101540835000_378.jul06_19.e069722.69","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1513-8"}],"updated-by":[{"DOI":"10.1136\/bmj.o2190","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000}}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2022-069722","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2022-069722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:54:13Z","timestamp":1761987253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2022-069722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":69,"alternative-id":["10.1136\/bmj-2022-069722"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2022-069722","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}